UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of: ~~December~~January, ~~2016~~2017

Commission File Number 001-36575

MACROCURE LTD.

(Translation of Registrant’s name into English)

25 Hasivim Street
Petach Tikva 4959383, Israel

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

CONTENTS

OnClosing ~~December 19, 2016, a special general meeting~~ of ~~shareholders~~Merger (the “Special Meeting”) of Macrocure Ltd. (“Macrocure” or the “Company”) approved, by the applicable requisite majority under Israeli law, each of the four proposals brought before the shareholders of Macrocure at the Special Meeting. The proposals included a merger proposal pursuant to which Macrocure will, subject to the satisfaction or waiver of the conditions to closing, merge with ~~a wholly-owned subsidiary of~~ Leap Therapeutics, Inc. (“Leap”), a clinical stage immuno-oncology company, and become a wholly-owned subsidiary of Leap (collectively, the “Merger”). At the effective time of the Merger, Leap will become a public company whose shares are traded on NASDAQ (assuming the approval of its listing application, such approval being a condition to the consummation of the Merger).

~~Each~~On ofJanuary ~~the~~23, ~~proposals~~2017, ~~approved~~Macrocure atLtd., ~~the~~or ~~Special~~Macrocure, ~~Meeting~~announced ~~was~~that ~~described~~its inpreviously ~~the~~reported ~~Proxy~~merger ~~Statement,~~transaction ~~dated~~with ~~November~~a ~~25,~~wholly ~~2016~~owned ~~(the~~subsidiary ~~“Proxy~~of ~~Statement”)~~Leap Therapeutics, ~~that~~Inc., ~~was~~or ~~distributed~~Leap, a clinical stage immuno-oncology company, pursuant to which Macrocure ~~shareholders~~is into ~~connection~~become ~~with~~a ~~Special~~wholly-owned ~~Meeting~~subsidiary ~~and~~of ~~annexed~~Leap, ashad ~~Exhibit~~been 99consummated.2 Pursuant to the transaction, each holder of ordinary shares, par value NIS 0.01 per share, of Macrocure’s, ~~Report~~or ordinary shares, is entitled to receive 0.1815 shares of ~~Foreign~~common ~~Private~~stock ~~Issuer~~of Leap, par value $0.001 per share, or Leap common stock, per ordinary share, plus cash in lieu of a fractional share of Leap common stock based on ~~Form~~a ~~6-K~~value ~~that~~of it$9.90 ~~furnished~~per toshare ~~the~~of ~~Securities~~Leap ~~and~~common ~~Exchange~~stock. ~~Commission~~The exchange ratio is based on ~~November~~a 25final net cash calculation, ~~2016~~as (of the ~~“Form~~closing, ~~6-K”)~~of $21.875 million.

The ~~Merger~~merger istransaction ~~subject~~was todescribed ~~certain~~further ~~closing conditions (~~in ~~addition to~~ the ~~foregoing~~final ~~approval~~prospectus, ofdated ~~the~~November ~~listing~~23, ~~application~~2016, offiled by Leap bywith ~~NASDAQ)~~the ~~which~~Securities ~~were~~and ~~described~~Exchange inCommission, ~~the~~or ~~Proxy~~SEC, ~~Statement.~~on InNovember ~~addition~~23, 2016 pursuant to Rule 424(b)(3) under ~~Israeli~~the ~~law,~~Securities atAct ~~least~~of 301933, ~~days~~as ~~must~~amended, ~~elapse~~and ~~after~~in ~~the~~Macrocure’s ~~approval~~proxy ofstatement, ~~the~~dated ~~Merger~~November by25, ~~the~~2016, ~~shareholders~~for ofits ~~Macrocure~~special ~~before~~general ~~the~~meeting ~~Merger~~of ~~may~~shareholders ~~become~~that ~~effective.~~took ~~Macrocure~~place ~~and~~on ~~Leap~~December ~~presently~~19, ~~expect~~2016, ~~subject~~which toproxy ~~the~~statement ~~timely~~was ~~satisfaction~~annexed oras ~~waiver~~Exhibit 99.2 to Macrocure’ Report of ~~all~~Foreign ~~conditions~~Private toIssuer ~~closing,~~on toForm 6-K ~~complete~~that ~~the~~was ~~transaction~~furnished ~~during~~to the ~~latter~~SEC ~~half~~on ofNovember ~~January~~25, ~~2017~~2016.

~~The~~Macrocure ~~information~~has ~~set~~notified ~~forth~~NASDAQ inof ~~this~~the ~~Report~~completion of ~~Foreign~~the ~~Private~~merger, ~~Issuer~~and trading in Macrocure’s ordinary shares on ~~Form~~NASDAQ ~~6-K~~has isceased. Macrocure ~~hereby~~has ~~incorporated~~also byrequested ~~reference~~that ~~into~~NASDAQ ~~Macrocure’s~~file ~~Registration~~a ~~Statement~~delisting application on Form ~~S-8~~25 (with the SEC ~~File~~to Noreport the delisting of the ordinary shares from NASDAQ. ~~333-200173)~~Macrocure ~~and~~furthermore isexpects to beterminate athe ~~part~~registration ~~thereof~~of ~~from~~its ordinary shares under the ~~date~~Securities onExchange ~~which~~Act ~~this~~of ~~Report~~1934, isas ~~furnished~~amended, and to ~~the~~therefore ~~extent~~cease ~~not~~to ~~superseded~~report byto ~~documents~~the orSEC, ~~reports~~approximately ~~subsequently~~10 ~~filed~~days orafter ~~furnished~~the closing of the merger.

~~CAUTIONARY~~NASDAQ ~~NOTE~~has ~~REGARDING~~approved ~~FORWARD-LOOKING~~the ~~STATEMENTS~~listing of the Leap common stock, and trading in Leap common stock is expected to begin on January 24, 2017, under the trading symbol “LPTX”.

~~Information~~A ~~contained~~press inrelease ~~this~~issued ~~Form~~by 6-K includes forward-looking statements that are not historical facts, such as whether shares of Leap will be listed for trading on NASDAQ and assumptions related to regulatory authorizations. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on Macrocure’s ~~current knowledge and its present beliefs and expectations regarding possible future events and are subject~~ to ~~risks,~~announce ~~uncertainties, and assumptions. Actual results and~~ the ~~timing~~consummation of ~~events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to,~~ the ~~expected timing and likelihood of completion of the proposed~~ Merger, ~~the~~has ~~occurrence~~been offurnished ~~any~~together ~~event,~~with ~~change,~~this orReport ~~other circumstance that could result in the termination~~ of ~~the~~Foreign ~~merger~~Private ~~agreement,~~Issuer ~~receipt~~on and timing of any required governmental or regulatory approvals relating to the listing of Leap’s common stock or otherwise relating to the Merger, the anticipated amount needed to finance the combined company’s future operations, unexpected results of clinical trials, delays or denial in regulatory approval process, or additional competition in the market. The forward-looking statements made herein speak only as of the date of this Form 6-K~~, and Macrocure undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.~~:

Exhibit No.

Exhibit Title

99.1	Press release entitled “Macrocure and Leap Therapeutics Complete Merger,” dated January 23, 2017.

The information set forth in this Report of Foreign Private Issuer on Form 6-K is hereby incorporated by reference into Macrocure’s Registration Statement on Form S-8 (SEC File No. 333-200173), and is to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MACROCURE LTD.
Date: December 19, 2016	By:	/s/ Shai Lankry
Date: January 23, 2017	By:	/s/ Shai Lankry
	Name:	Shai Lankry
	Title:	Chief Financial Officer

Filing Compare · Macrocure Ltd.